Baxalta Suit Over Roche’s Hemlibra Revived by Appeals Court (1)

A U.S. appeals court ruled that Hemlibra, a hemophilia treatment owned by Roche’s Genentech, must face revived allegations that it infringes a patent Baxalta owns for an antibody that increases blood-clotting activity.

• Baxalta, which is seeking royalties on U.S. sales of Hemlibra, had appealed a trial court decision in Delaware
• The case was remanded for further proceedings under proper understanding of terms “antibody” and “antibody fragment,” according to opinion issued Thursday by the U.S. Court of Appeals for the Federal Circuit
• Baxalta had conceded that, under the trial court’s interpretation, it wouldn’t be able to win the case, a ...